<!DOCTYPE html>
<html lang="en-US"><head>
		<meta charset="UTF-8">
		<title>FR940617-1-00098</title>
	</head>
	<body>
		<main>
			<p><!-- PJG STAG 4702 -->  <!-- PJG ITAG l=11 g=1 f=1 --> (B) The satisfactory performance of the test product as  <!-- PJG 0012 frnewline --> assessed by the results of the MIC studies, the time-kill  <!-- PJG 0012 frnewline --> studies, and the simulated in vivo clinical trials of organisms  <!-- PJG 0012 frnewline --> representing the resident microbial flora can then be used to  <!-- PJG 0012 frnewline --> assess the effectiveness of the test product for the transient  <!-- PJG 0012 frnewline --> microbial flora most commonly encountered in the clinical  <!-- PJG 0012 frnewline --> setting. This procedure is required because methods, other than  <!-- PJG 0012 frnewline --> the health-care personnel hand test, do not exist for assessing  <!-- PJG 0012 frnewline --> the in vivo effectiveness of test products versus the transient  <!-- PJG 0012 frnewline --> microbial flora.  <!-- PJG 0012 frnewline --> (C) It is recognized that a generally accepted or  <!-- PJG 0012 frnewline --> standardized method that may be used in conducting in vitro time-kill studies is not available, but the agency encourages the  <!-- PJG 0012 frnewline --> submission of proposed methods that may be considered applicable  <!-- PJG 0012 frnewline --> to this test. Many variables that should be considered in the  <!-- PJG 0012 frnewline --> development of a method have been addressed for antibiotics and  <!-- PJG 0012 frnewline --> are also applicable to these products. Such variables are  <!-- PJG 0012 frnewline --> described by Schoenknecht, F. D., L. D. Sabath, and C.  <!-- PJG 0012 frnewline --> Thornsberry, ``Susceptibility Tests: Special Tests,'' in the  <!-- PJG 0012 frnewline --> ``Manual of Clinical Microbiology,'' 4th ed., edited by E. H.  <!-- PJG 0012 frnewline --> Lennette et al., American Society for Microbiology, Washington,  <!-- PJG 0012 frnewline --> pp. 1,000&hyph;1,008, which is incorporated by reference in accordance  <!-- PJG 0012 frnewline --> with 5 U.S.C. 552(a) and 1 CFR part 51. Copies are available  <!-- PJG 0012 frnewline --> from the American Society for Microbiology, Washington, DC, or  <!-- PJG 0012 frnewline --> may be examined at the Center for Drug Evaluation and Research,  <!-- PJG 0012 frnewline --> 7520 Standish Pl., suite 201, Rockville, MD, or at the Office of  <!-- PJG 0012 frnewline --> the Federal Register, 800 North Capitol St. NW., suite 700,  <!-- PJG 0012 frnewline --> Washington, DC.  <!-- PJG 0012 frnewline --> (D) The procedure to be used is to incorporate the  <!-- PJG 0012 frnewline --> recommendations described on page 1,004 of the chapter in the  <!-- PJG 0012 frnewline --> ``Manual of Clinical Microbiology'' cited in paragraph  <!-- PJG 0012 frnewline --> (a)(1)(iv)(C) of this section with the following modifications.  <!-- PJG 0012 frnewline --> Because the time frames of greatest interest for antiseptic drug  <!-- PJG 0012 frnewline --> products intended for health-care personnel handwash, surgical  <!-- PJG 0012 frnewline --> hand scrub, and patient preoperative skin preparation use are 1  <!-- PJG 0012 frnewline --> to 30 minutes, the time-kill studies are to focus on these time  <!-- PJG 0012 frnewline --> frames and are to include enumerations at times 0, 3, 6, 9, 12,  <!-- PJG 0012 frnewline --> 15, 20, and 30 minutes. Enumerate the bacteria in the sampling  <!-- PJG 0012 frnewline --> solution by a standard plate count procedure such as that  <!-- PJG 0012 frnewline --> described in ``Standard Methods for the Evaluation of Dairy  <!-- PJG 0012 frnewline --> Products'' (available from American Public Health Association,  <!-- PJG 0012 frnewline --> Inc., 1015 15th St. NW., Washington, DC 20005), but using  <!-- PJG 0012 frnewline --> soybean-casein digest agar and a suitable inactivator for the  <!-- PJG 0012 frnewline --> antimicrobial where necessary. The suitability of the  <!-- PJG 0012 frnewline --> inactivator is to be demonstrated using a procedure such as  <!-- PJG 0012 frnewline --> described in E 1054, ``Test Methods for Evaluating Inactivators of  <!-- PJG 0012 frnewline --> Antimicrobial Agents Used in Disinfectant, Sanitizer, and  <!-- PJG 0012 frnewline --> Antiseptic Products,'' in ``Annual Book of ASTM Standards,'' vol.  <!-- PJG 0012 frnewline --> 11.04, which is incorporated by reference in accordance with 5  <!-- PJG 0012 frnewline --> U.S.C. 552(a) and 1 CFR part 51. Copies are available from The  <!-- PJG 0012 frnewline --> American Society for Testing and Materials, 1916 Race St., Philadelphia, PA 19103&hyph;1187, or may be examined at the Center for  <!-- PJG 0012 frnewline --> Drug Evaluation and Research (HFD&hyph;810), 5600 Fishers Lane,  <!-- PJG 0012 frnewline --> Rockville, MD, or at the Office of the Federal Register,  <!-- PJG 0012 frnewline --> 800 North Capitol St. NW., suite 700, Washington, DC. The  <!-- PJG 0012 frnewline --> battery of organisms selected is to represent the resident  <!-- PJG 0012 frnewline --> microbial flora most commonly encountered under actual use  <!-- PJG 0012 frnewline --> conditions of the test product and the transient microbial flora  <!-- PJG 0012 frnewline --> most likely to be encountered by health-care professionals in  <!-- PJG 0012 frnewline --> clinical settings. Therefore, the micro-organisms to be used in  <!-- PJG 0012 frnewline --> these time-kill studies are to be the standard ATCC strains  <!-- PJG 0012 frnewline --> identified in paragraph (a)(1)(ii) of this section. The drug  <!-- PJG 0012 frnewline --> concentration to be tested should be a tenfold dilution of the  <!-- PJG 0012 frnewline --> finished product.  <!-- PJG 0012 frnewline --> (2)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> In vivo testing. <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  The following tests, approximating  <!-- PJG 0012 frnewline --> use conditions for the clinical evaluation of each label claim of  <!-- PJG 0012 frnewline --> the finished product, are to be carried out using the finished  <!-- PJG 0012 frnewline --> product for the product classes specified.  <!-- PJG 0012 frnewline --> (i) Test method for the evaluation of surgical hand scrub  <!-- PJG 0012 frnewline --> drug products. The procedure to be used (paragraph (b)(1)(iii)  <!-- PJG 0012 frnewline --> of this section) is a modification of the standard testing  <!-- PJG 0012 frnewline --> procedure for the evaluation of surgical hand scrub drug products  <!-- PJG 0012 frnewline --> published by the American Society for Testing and Materials,  <!-- PJG 0012 frnewline --> ``Standard Method for Evaluation of Surgical Hand Scrub  <!-- PJG 0012 frnewline --> Formulation, Designation E 1115,'' in ``The Annual Book of ASTM  <!-- PJG 0012 frnewline --> Standards,'' vol. 11.04, American Society for Testing and  <!-- PJG 0012 frnewline --> Materials, Philadelphia, pp. 201&hyph;204, 1986, which is incorporated  <!-- PJG 0012 frnewline --> by reference in accordance with 5 U.S.C. 552(a) and 1 CFR part  <!-- PJG 0012 frnewline --> 51. Copies are available from The American Society for Testing  <!-- PJG 0012 frnewline --> and Materials, 1916 Race St., Philadelphia, PA 19103&hyph;1187, or  <!-- PJG 0012 frnewline --> may be examined at the Center for Drug Evaluation and Research,  <!-- PJG 0012 frnewline --> 7520 Standish Pl., suite 201, Rockville, MD, or at the Office of  <!-- PJG 0012 frnewline --> the Federal Register, 800 North Capitol St. NW., suite 700,  <!-- PJG 0012 frnewline --> Washington, DC.  <!-- PJG 0012 frnewline --> (ii) Test method for the evaluation of health-care  <!-- PJG 0012 frnewline --> antiseptic handwash or health-care personnel handwash drug  <!-- PJG 0012 frnewline --> products. The procedure to be used (paragraph (b)(2)(iii) of  <!-- PJG 0012 frnewline --> this section) is a modification of the standard testing procedure  <!-- PJG 0012 frnewline --> for the evaluation of health-care antiseptic handwash drug  <!-- PJG 0012 frnewline --> products published by the American Society for Testing and  <!-- PJG 0012 frnewline --> Materials, ``Standard Method for the Evaluation of Health Care  <!-- PJG 0012 frnewline --> Handwash Formulation, Designation E1174,'' in ``The Annual Book of  <!-- PJG 0012 frnewline --> ASTM Standards,'' vol. 11.04, American Society for Testing and  <!-- PJG 0012 frnewline --> Materials, Philadelphia, pp. 209&hyph;212, 1987, which is incorporated  <!-- PJG 0012 frnewline --> by reference in accordance with 5 U.S.C. 552(a) and 1 CFR part  <!-- PJG 0012 frnewline --> 51. Copies are available from The American Society for Testing  <!-- PJG 0012 frnewline --> and Materials, 1916 Race St., Philadelphia, PA 19103&hyph;1187, or  <!-- PJG 0012 frnewline --> may be examined at the Center for Drug Evaluation and Research,  <!-- PJG 0012 frnewline --> 7520 Standish Pl., suite 201, Rockville, MD, or at the Office of  <!-- PJG 0012 frnewline --> the Federal Register, 800 North Capitol St. NW., suite 700,  <!-- PJG 0012 frnewline --> Washington, DC.  <!-- PJG 0012 frnewline --> (iii) Test method for the evaluation of patient  <!-- PJG 0012 frnewline --> preoperative skin preparation drug products. The procedure to be  <!-- PJG 0012 frnewline --> used (paragraph (b)(3)(iii) of this section) is a modification of  <!-- PJG 0012 frnewline --> the standard testing procedure for the evaluation of patient  <!-- PJG 0012 frnewline --> preoperative skin preparations published by the American Society  <!-- PJG 0012 frnewline --> for Testing and Materials, ``Standard Test Method for the Evaluation of a Patient Preoperative Skin Preparation,  <!-- PJG 0012 frnewline --> Designation 1173,'' in ``The Annual Book of ASTM Standards,'' vol.  <!-- PJG 0012 frnewline --> 11.04, American Society for Testing and Materials, Philadelphia,  <!-- PJG 0012 frnewline --> pp. 205&hyph;208, 1987, which is incorporated by reference in  <!-- PJG 0012 frnewline --> accordance with 5 U.S.C. 552(a) and 1 CFR part 51. Copies are  <!-- PJG 0012 frnewline --> available from The American Society for Testing and Materials,  <!-- PJG 0012 frnewline --> 1916 Race St., Philadelphia, PA 19103&hyph;1187, or may be examined  <!-- PJG 0012 frnewline --> at the Center for Drug Evaluation and Research, 7520 Standish  <!-- PJG 0012 frnewline --> Pl., suite 201, Rockville, MD, or at the Office of the Federal  <!-- PJG 0012 frnewline --> Register, 800 North Capitol St. NW., suite 700, Washington, DC.  <!-- PJG 0012 frnewline --> (b)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Specific testing criteria <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> _(1)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Effectiveness testing  <!-- PJG 0012 frnewline --> of a surgical hand scrub. <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  A surgical hand scrub drug product in  <!-- PJG 0012 frnewline --> finished form suitable for topical application will be recognized  <!-- PJG 0012 frnewline --> as effective provided that the formulated drug product at its  <!-- PJG 0012 frnewline --> recommended use concentration:  <!-- PJG 0012 frnewline --> (i) Contains an ingredient in &sect;333.414 (a) or (b).  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG /STAG --></p>
		</main>
</body></html>
            